Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Abstract Prognosis of Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in the
elderly has improved during the imatinib era. We investigated dasatinib, another potent …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary
greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics …

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 …

Background Trials of imatinib have provided evidence of activity in adults with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given …